127 related articles for article (PubMed ID: 25397556)
1. Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
Pinnetti C; Di Giambenedetto S; Maggiolo F; Lorenzini P; Fabbiani M; Tommasi C; Latini A; Ammassari A; Loiacono L; Sterrantino G; Bellagamba R; Boumis E; Antinori A; Zaccarelli M
J Int AIDS Soc; 2014; 17(4 Suppl 3):19812. PubMed ID: 25397556
[TBL] [Abstract][Full Text] [Related]
2. 3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.
Gagliardini R; Bandera A; Zaccarelli M; Sterrantino G; Latini A; D'Avino A; Lapadula G; Antinori A; Cauda R; De Luca A; Gori A; Di Giambenedetto S; Fabbiani M
Antivir Ther; 2018; 23(2):139-148. PubMed ID: 28799920
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
[TBL] [Abstract][Full Text] [Related]
4. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
[TBL] [Abstract][Full Text] [Related]
5. Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis.
Stellbrink HJ; Antinori A; Pozniak A; Flamm J; Bredeek F; Patel K; Garner W; Piontkowsky D
J Int AIDS Soc; 2014; 17(4 Suppl 3):19793. PubMed ID: 25397537
[TBL] [Abstract][Full Text] [Related]
6. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
[TBL] [Abstract][Full Text] [Related]
7. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
Sculier D; Gayet-Ageron A; Battegay M; Cavassini M; Fehr J; Hirzel C; Schmid P; Bernasconi E; Calmy A;
BMC Infect Dis; 2017 Jul; 17(1):476. PubMed ID: 28683720
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S
Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.
Bernaud C; Khatchatourian L; Rodallec A; Hall N; Perre P; Morrier M; Pineau S; Jovelin T; André-Garnier E; Raffi F; Allavena C
Infect Dis (Lond); 2016 Oct; 48(10):754-9. PubMed ID: 27389932
[TBL] [Abstract][Full Text] [Related]
10. Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.
Pérez-Hernández IA; Palacios R; Mayorga M; González-Doménech CM; Castaño M; Rivero A; Del Arco A; Lozano F; Santos J
J Int AIDS Soc; 2014; 17(4 Suppl 3):19795. PubMed ID: 25397539
[TBL] [Abstract][Full Text] [Related]
11. Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.
Menezes P; Mollan K; Hoffman E; Xie Z; Wills J; Marcus C; Rublein J; Hudgens M; Eron JJ
AIDS Res Hum Retroviruses; 2018 Jun; 34(6):481-485. PubMed ID: 29607652
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
Porter DP; Toma J; Tan Y; Solberg O; Cai S; Kulkarni R; Andreatta K; Lie Y; Chuck SK; Palella F; Miller MD; White KL
HIV Clin Trials; 2016 Feb; 17(1):29-37. PubMed ID: 26899540
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
[TBL] [Abstract][Full Text] [Related]
14. Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.
Amiel C; Schneider V; Guessant S; Hamidi M; Kherallah K; Lebrette MG; Chas J; Lependeven C; Pialoux G
J Antimicrob Chemother; 2014 Dec; 69(12):3335-9. PubMed ID: 25114163
[TBL] [Abstract][Full Text] [Related]
15. Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis.
Arribas J; Rizzardini G; Arasteh K; Zurawski C; Dietz C; Pontani D; Garner W; Nguyen T
J Int AIDS Soc; 2014; 17(4 Suppl 3):19805. PubMed ID: 25397549
[TBL] [Abstract][Full Text] [Related]
16. Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.
Sweet D; Song J; Zhong Y; Signorovitch J
J Int AIDS Soc; 2014; 17(4 Suppl 3):19537. PubMed ID: 25394046
[TBL] [Abstract][Full Text] [Related]
17. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.
Gianotti N; Poli A; Nozza S; Spagnuolo V; Tambussi G; Bossolasco S; Cinque P; Maillard M; Cernuschi M; Galli L; Lazzarin A; Castagna A
J Int AIDS Soc; 2015; 18(1):20037. PubMed ID: 26232000
[TBL] [Abstract][Full Text] [Related]
19. Switching from an EFV-based STR to a RPV-based STR is effective, safe and improves HIV patients health status.
Maggiolo F; Di Matteo S; Bruno G; Astuti N; Di Filippo E; Valenti D; Colombo G
J Int AIDS Soc; 2014; 17(4 Suppl 3):19798. PubMed ID: 25397542
[TBL] [Abstract][Full Text] [Related]
20. The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study.
Rokx C; Blonk M; Verbon A; Burger D; Rijnders BJ
J Int AIDS Soc; 2014; 17(4 Suppl 3):19789. PubMed ID: 25397533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
